149 related articles for article (PubMed ID: 38833106)
1. Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study.
Ononogbu O; Akindele O; Yazdanfard S; Fatima B; Abughosh S; Trivedi MV
Support Care Cancer; 2024 Jun; 32(7):407. PubMed ID: 38833106
[TBL] [Abstract][Full Text] [Related]
2. Adherence to immunomodulatory drugs in patients with multiple myeloma.
Cransac A; Aho S; Chretien ML; Giroud M; Caillot D; Boulin M
PLoS One; 2019; 14(3):e0214446. PubMed ID: 30917164
[TBL] [Abstract][Full Text] [Related]
3. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Dashputre AA; Gatwood KS; Gatwood J
J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965
[TBL] [Abstract][Full Text] [Related]
4. Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.
Mian H; Fiala M; Wildes TM
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):98-104.e1. PubMed ID: 31843543
[TBL] [Abstract][Full Text] [Related]
5. [Immunomodulator drugs for the treatment of multiple myeloma].
Fernández-Lázaro D; Fernández-Lázaro CI; Caballero García A; Córdova Martínez A
Rev Med Chil; 2018 Dec; 146(12):1444-1451. PubMed ID: 30848748
[TBL] [Abstract][Full Text] [Related]
6. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
7. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma.
Mark T; Falkenstein A; Kish J
Future Oncol; 2022 Feb; 18(5):553-564. PubMed ID: 34787472
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma.
Anderson SM; Beck B; Sterud S; Lockhorst R; Ngorsuraches S
J Oncol Pharm Pract; 2019 Jun; 25(4):806-812. PubMed ID: 29486638
[TBL] [Abstract][Full Text] [Related]
10. Adherence to oral antidiabetic medications in the pediatric population with type 2 diabetes: a retrospective database analysis.
Adeyemi AO; Rascati KL; Lawson KA; Strassels SA
Clin Ther; 2012 Mar; 34(3):712-9. PubMed ID: 22381712
[TBL] [Abstract][Full Text] [Related]
11. Effect of a Smart Pill Bottle and Pharmacist Intervention on Medication Adherence in Patients with Multiple Myeloma New to Lenalidomide Therapy.
Mauro J; Mathews KB; Sredzinski ES
J Manag Care Spec Pharm; 2019 Nov; 25(11):1244-1254. PubMed ID: 31663462
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.
Lee C; Grigorian M; Nolan R; Binder G; Rice G
J Med Econ; 2016; 19(4):397-402. PubMed ID: 26652728
[TBL] [Abstract][Full Text] [Related]
13. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Roziaková L; Mistrík M; Bátorová A
Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
[TBL] [Abstract][Full Text] [Related]
14. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Zweegman S; van der Holt B; Mellqvist UH; Salomo M; Bos GM; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden AW; Deenik W; Gruber A; Coenen JL; Plesner T; Klein SK; Tanis BC; Szatkowski DL; Brouwer RE; Westerman M; Leys MR; Sinnige HA; Haukås E; van der Hem KG; Durian MF; Mattijssen EV; van de Donk NW; Stevens-Kroef MJ; Sonneveld P; Waage A
Blood; 2016 Mar; 127(9):1109-16. PubMed ID: 26802176
[TBL] [Abstract][Full Text] [Related]
15. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Dimopoulos MA; Schjesvold F; Doronin V; Vinogradova O; Quach H; Leleu X; Montes YG; Ramasamy K; Pompa A; Levin MD; Lee C; Mellqvist UH; Fenk R; Demarquette H; Sati H; Vorog A; Labotka R; Du J; Darif M; Kumar S
Blood Cancer J; 2022 Jan; 12(1):9. PubMed ID: 35075109
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of asthma medication adherence rates and strategies to improve adherence in the underserved population at a Federally Qualified Health Center.
Bidwal M; Lor K; Yu J; Ip E
Res Social Adm Pharm; 2017; 13(4):759-766. PubMed ID: 27595427
[TBL] [Abstract][Full Text] [Related]
17. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA;
N Engl J Med; 2012 May; 366(19):1759-69. PubMed ID: 22571200
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
19. Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma.
Kourelis TV; Kumar SK; Srivastava G; Gertz MA; Lacy MQ; Buadi FK; Kyle RA; Dispenzieri A
Leukemia; 2014 Feb; 28(2):455-7. PubMed ID: 24150218
[No Abstract] [Full Text] [Related]
20. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
